Mitsubishi Tanabe Pharma presents RADICAVA ORS data at NASP 2024 in Nashville

In October 2024, Mitsubishi Tanabe Pharma America, Inc. announced two presentations at the National Association of Specialty Pharmacy Annual Meeting in Nashville, Tennessee. The presentations will focus on RADICAVA ORS, an oral formulation of edaravone, which has been recognized by the FDA for its significant contribution to patient care in treating Amyotrophic Lateral Sclerosis (ALS). An analysis utilizing Optum’s de-identified Clinformatics Data Mart will provide insights into the real-world impact of this treatment on patients. RADICAVA is traditionally administered via intravenous infusion in 28-day cycles, but the new oral suspension offers a more convenient option for patients. The marketing authorization for RADICAVA Oral Suspension was granted in Canada and Switzerland in late 2022 and early 2023, respectively, indicating a growing acceptance of this treatment option in various markets. The company emphasizes the importance of monitoring for hypersensitivity reactions and potential fetal harm during pregnancy, highlighting the need for careful patient management. Overall, the presentations at the NASP Annual Meeting aim to enhance understanding of RADICAVA ORS and its role in improving the quality of life for individuals with ALS.